T‐cell‐rich HLA‐haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome‐positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Pediatric Blood & Cancer

• Publication date

  2017-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pbc.26242PMID 27781393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia

  2016cited by this paper
• Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph+ALL04

  2015cited by this paper
• T-cell-replete haploidentical stem cell transplantation is highly efficacious for relapsed and refractory childhood acute leukaemia

  2014cited by this paper
• Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome‐positive acute lymphoblastic leukemia

  2014cited by this paper
• Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

  2014cited by this paper
• Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

  2013cited by this paper
• Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study

  2012cited by this paper
• Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

  2012cited by this paper
• Feasibility of tacrolimus, methotrexate, and prednisolone as a graft‐versus‐host disease prophylaxis in non‐T‐cell‐depleted haploidentical hematopoietic stem cell transplantation for children

  2011cited by this paper
• Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.

  2009cited by this paper
• Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome‐positive acute lymphoblastic leukemia (ALL)

  2009cited by this paper
• Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.

  2008cited by this paper
• Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.

  2007cited by this paper
• Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.

  2006cited by this paper
• Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.

  2004cited by this paper
• A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

  2002cited by this paper

• Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study

  2020cites this paper